optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia
Published 9 years ago • 478 plays • Length 4:33Download video MP4
Download video MP3
Similar videos
-
2:03
update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia
-
4:42
chronic myeloid leukemia (cml) - treatment - tyrosine kinase (tk) inhibitors
-
3:12
second-generation tyrosine kinase inhibitors for chronic myeloid leukemia
-
34:51
fine-tuning chronic lymphocytic leukemia management: optimising bruton tyrosine kinase inhibitor ...
-
1:24
considerations for tki choice in frontline and r/r cml
-
7:27
menin inhibitors in aml: mechanism of action, the current key data, and predicting efficacy
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
1:24
mechanisms of resistance to flt3 inhibitors in aml and strategies to overcome this
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
2:42
optimizing maintenance therapy in multiple myeloma: an analysis from the preamble registry
-
1:17
optimizing initial therapy in cll: time-limited, all-oral approaches
-
1:04
continuous treatment with flt3 inhibitors for patients with flt3-mutated aml undergoing allosct
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
1:02
optimizing cns prophylaxis in the treatment of all
-
4:20
therapy-related all: etiology, prognosis, and treatment
-
4:31
optimizing conventional chemotherapy in all
-
4:02
testing for bcr::abl kinase mutations in cml and how they impact tki resistance
-
1:12
insights into the optimal management of cll: the importance of patient characteristics